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ABSTRACT
Introduction: Economic evaluations are
becoming increasingly important due to
limitations in economic resources, the expense
of many new treatments, the need to allocate
health spending as effectively as possible, and
the need to inform decision makers. Based on
the data from the apixaban studies (ARISTOTLE
and AVERROES), several economic evaluations
have been performed in various countries to
demonstrate the efficacy of apixaban versus
warfarin and aspirin or other new oral
anticoagulants (NOACs) for preventing stroke
in patients with non-valvular atrial fibrillation
(NVAF).The aim of this study was to perform a
systematic literature review of published
economic evaluations with apixaban in the
indication of stroke prevention in patients
with NVAF.
Methods: A search in PubMed, Cochrane
Library, Google Scholar, and Index Medicus
Espan˜ol was conducted in June 2015. Inclusion
and exclusion criteria were established. The
main characteristics were recorded for all
relevant articles after being reviewed. In
addition, a weighted version of the
Drummond’s checklist was used to further
assess the quality of the selected studies.
Results: After review, 26 cost-effectiveness
analyses through Markov models were
included; the identified economic evaluations
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represent different willingness-to-pay (WTP)
thresholds, discount rates, medical costs, and
healthcare systems. Apixaban was compared
with warfarin/acenocoumarol in 7 of them
(27%), with warfarin/NOACs in 14 (54%), with
aspirin in 2 (8%), and with warfarin/aspirin in 3
(11%). Models were conducted from Europe
(69%), USA (23%), Australia (4%), and Latin
America (4%). All models reported cost/
quality-adjusted life years (QALYs) gained,
92% reported using a payer perspective, and
8% using a societal perspective; the median
quality score of the selected studies was 89 (out
of 119), with a range of 55–103. In models
performed in Europe, incremental
cost-effectiveness ratios (ICERs) of apixaban
versus warfarin ranged from €5607/QALY to
€57,245/QALY, while ICERs versus aspirin
ranged from being dominant to €7334/QALY.
In models carried out in the USA, ICERs of
apixaban versus warfarin ranged from being
dominant to $93,063/QALY.
Conclusion: Different cost-effectiveness
analyses suggest that apixaban is a
cost-effective therapeutic option according to
the WTP thresholds used in countries where
cost-effectiveness analyses, were performed.
Funding: BMS and Pfizer.
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INTRODUCTION
Apixaban is a new oral anticoagulant (NOAC). It
is a direct factor Xa inhibitor with rapid
absorption and a 12-h half-life. A total of 25%
is eliminated through renal excretion. Apixaban
demonstrated its superior efficacy and safety
versus warfarin (gold standard) in preventing
stroke in patients with non-valvular atrial
fibrillation (NVAF) in the ARISTOTLE study [1]
and versus aspirin in the AVERROES study [2]
(ClinicalTrials.gov identifiers: NCT00412984
and NCT00496769, respectively). Apixaban
belongs to the new generation of
anticoagulants with fixed-dose oral
administration not requiring laboratory
controls and having a little interaction with
other drugs and foods [3].
Traditionally, healthcare companies were
required to provide evidence to demonstrate
product safety, efficacy, and quality for
registration and reimbursement purposes.
Increasingly, demonstrating value-for-money,
which requires companies to conduct
economic evaluations to support the
reimbursement process, has been added,
increasing the importance of health economic
evaluations. Some clinical guidelines [4] take
cost-effectiveness data into consideration when
positioning therapies for stroke prevention in
NVAF. Therefore, an important step in
determining the place of NOACs in clinical
practice is to evaluate their cost-effectiveness in
terms of their effect on healthcare
decision-making and hence on health
outcomes.
In addition, economic evaluations are
becoming increasingly important due to
limitations in economic resources, the expense
of many new treatments, the need to allocate
health spending as effectively as possible, and
the need to inform decision makers.
Based on the data from the apixaban studies
(ARISTOTLE [1] and AVERROES [2]), several
economic evaluations have been performed in
various countries to demonstrate the efficiency
of apixaban versus warfarin and aspirin or other
NOACs for preventing stroke in patients with
NVAF.
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The aim of this study was to perform a
systematic literature review of published
economic evaluations with apixaban indicated
for stroke prevention in patients with NVAF.
METHODS
Search Strategy
Once the search topicwas established: ‘‘Economic
evaluation of apixaban in the indication of stroke
prevention in patients with NVAF in Spain and in
other countries’’, we conducted a systematic
literature search in PubMed, Cochrane Library,
Google Scholar, and Index Medicus Espan˜ol (IME)
in June 2015 based on the following strategy:
‘‘(apixaban)AND (cost-effectivenessORefficiency
OR economic evaluation) AND (non-valvular
atrial fibrillation)’’. The literature search was not
restricted by publication year.
Inclusion and Exclusion Criteria
The following inclusion criteria were considered
(all must have been met):
• Economic evaluations of apixaban
performed in any country;
• Economic evaluations of apixaban in the
indication of stroke prevention in patients
with NVAF;
• Any type of economic evaluation of
apixaban (cost minimization analysis,
cost-effectiveness analysis, cost-utility (CU)
analysis, and cost-benefit analysis);
• Economic evaluations of apixaban or
apixaban and other NOACs versus the gold
standard (aspirin or warfarin or coumarin
derivative) and other NOACs;
• Original articles.
The following exclusion criteria were
considered (none must have been met):
• Economic evaluations of other NOACs
excluding apixaban (dabigatran,
rivaroxaban, and edoxaban);
• Economic evaluations of other
anticoagulants excluding apixaban
(warfarin, acenocoumarol, heparins, etc.);
• Other types of pharmacoeconomic studies
with apixaban (budget impact analysis, cost/
burden of disease studies, etc.);
• Economic evaluations of apixaban in other
indications aside from the target indication
of this study (venous thromboembolism
[VTE] prevention in patients undergoing
total hip or knee replacement, VTE
treatment, etc.);
• Article language other than Spanish, English,
French, Portuguese, or Italian;
• Review articles, letters, commentaries,
editorials, and papers that only report a
study methodology without a result.
Data Extraction
The extraction process consisted of three steps
once studies were identified after the search.
First, some studies were excluded just by
reading the title, mostly in the case of
repeated records. Then, the inclusion and
exclusion criteria were applied to limit the
records to those that met the criteria. In a
second review, the same criteria were applied
after reading the selected abstracts to identify
relevant studies. Finally, we proceeded to read
the full articles of the selected records.
For all relevant articles after review, the main
characteristics were recorded: title, authors,
country, year of publication, journal (number,
pages, etc.), main objective, type of evaluation,
time horizon, type of model, perspective,
comparator(s) against apixaban, sensitivity
analysis, main results (incremental
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cost-effectiveness ratio [ICER]), and main
conclusions.
The search was summarized in a
CONSORT-style flowchart (PRISMA) [5].
Quality Assessment
In addition, a weighted version of Drummond’s
checklist [6] was used to further assess the
quality of the selected studies [7]. The
checklist is used specifically to assess economic
evaluation studies, and it was divided into three
main sections: study design, data collection,
and the analysis and interpretation of results.
The list consists of 35 items. The weighted
version was used in the previous studies [8, 9]
and assigns a maximum overall score of 119
(maximum scores of 26 for study design, 48 for
analysis and interpretation of results, and 45 for
data collection).
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of




With the aforementioned search strategy:
‘‘(apixaban) AND (cost-effectiveness OR
efficiency OR economic evaluation) AND
(non-valvular atrial fibrillation)’’, 129 articles
were found (53 articles from PubMed, 10 articles
from Cochrane Library, 43 articles from Google
Scholar, and 23 articles from the IME).
In the first review, after reading the titles of
all the articles found, nine repeated articles were
excluded from the four databases. After
applying the inclusion and exclusion criteria,
80 more articles were excluded for the following
reasons:
• 6 articles were economic evaluations of other
NOACs;
• 10 articles were economic evaluations of
apixaban for indications other than stroke
prevention in patients with NVAF;
• 61 articles were not appropriate (studies on
effectiveness or efficacy, on costs, in
languages others than those listed in the
exclusion criteria, on pharmacotherapeutic
guidelines, etc.);
• 3 articles were review articles.
In the second review, after reading the
abstracts of the 40 articles selected after the
first review, 14 were discarded for not meeting
the inclusion criteria:
• 7 were review articles;
• 4 were not economic evaluations; they were
cost studies;
• 2 did not include apixaban among those
NOACs tested;
• 1 referred to another article already listed.
Finally, 26 articles were selected for full
reading. After reading the articles, none of
them were excluded (Fig. 1).
Drummond’s Checklist
Table 1 shows the quality assessment results of
the studies using the weighted version of
Drummond’s checklist [7]. All of the studies
clearly defined the research question (item 1),
the economic importance of the research
question (item 2), the viewpoints of the
analysis (item 3), the rationale for choosing
the alternative programs (item 4), and the
alternatives being compared (item 5). The
mean for the ‘‘Study design’’ section was 20
out of 26, with a maximum of 26 and a
minimum of 12. All studies referenced the
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source of the effectiveness estimates (item 8). In
all the studies, the details of either the clinical
trial or the meta-analysis of estimates are given
(items 9 and 10), the primary outcome measures
for the economic evaluation were reported
(item 11), as were the methods to assess health
states and other benefits (item 12), currency and
price data were reported (item 18), details of any
model used were given (item 20), and the
choice of the model used and the key
parameters, on which it was based were
referenced (item 21). In summary, the ‘‘Data
collection’’ section had a mean of 32 out of 45,
with a maximum of 42 and a minimum of 22.
The time horizon of costs and benefits was
stated (item 22), as was the discount rate (item
23). The approach to sensitivity analysis was
given (item 27). All the studies compared
Fig. 1 CONSORT-type ﬂowchart summarizing the study (PRISMA) [5]. The reasons for exclusion of records are
summarized in the text (‘‘Results’’ section)
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relevant alternatives (item 30) and reported
incremental analysis (item 31). Major
outcomes were presented in a disaggregated
and aggregated form (item 32) and studies
answered the study questions (item 33) and
presented conclusions (item 34). The mean for
the third section ‘‘Analysis and interpretation of
results’’ was 39, with a maximum of 42 and a
Table 1 Quality assessment results of the studies with the weighted Drummond’s checklist [7]
References Study design Data collection Analysis and interpretation results Final score
[10] 19 35 35 89
[11] 19 32 32 83
[12] 19 32 38 89
[13] 19 35 35 89
[14] 19 35 35 89
[15] 19 35 35 89
[16] 19 28 38 85
[17] 19 25 38 82
[18] 19 35 35 89
[19] 19 42 42 103
[20] 19 32 32 83
[21] 19 32 39 90
[22] 26 32 35 93
[23] 19 32 31 82
[24] 19 35 42 96
[25] 26 25 42 93
[26] 12 22 21 55
[27] 23 38 29 90
[28] 19 29 35 83
[29] 19 29 39 87
[30] 23 32 42 97
[31] 23 35 39 97
[32] 19 32 39 90
[33] 19 29 42 90
[34] 19 25 35 79
[35] 19 29 39 87
Median 89
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minimum of 21. According to the weighted
Drummond’s checklist, the median quality
score of selected studies was 89, with a
minimum score of 55, and a maximum score
of 103.
The most relevant information from the 26
selected articles is summarized in Appendix 1 in
the supplementary material.
Article Characteristics
The majority of cost-effectiveness evaluations
were published recently (3 in 2012, 4 in 2013,
14 in 2014, and 5 in 2015) and reported the
health economic data of apixaban in a very
large number of countries: US (5), UK (4), Spain
(3), Belgium (2), The Netherlands (2), Italy (2),
Canada (1), Australia (1), Germany (1), Norway
(1), France (1), Sweden (1), Slovenia (1), and
Argentina (1).
All selected articles except one, which used a
discrete events simulation model [26], used a
Markov model to extrapolate long-term data; all
the models derived effectiveness and safety data
from randomized clinical trials. The majority of
the models (73%) included 8–14 health states,
representing the main clinical outcomes in
anticoagulated patients with atrial fibrillation
(AF; ischemic stroke, hemorrhagic stroke,
transient ischemic attack, systemic embolism,
myocardial infarction, intracranial
hemorrhages, other major hemorrhages, and
minor bleeding).
All published evaluations except seven used
the perspective of the payer, including only
direct costs. Four studies [20, 29, 32, 34]
presented the results from a societal
perspective, and three studies [13–15]
presented both societal and payer perspectives.
All publications except four used a lifetime
horizon for the included subjects: two of them
used a time horizon of 20 years [25, 34], one
study used 30 years [32], and one study used a
1-year period and a 10-year period [25]. Utilities
were generally assigned on the basis of
previously published studies.
The articles by Dorian et al. [23] and Lip et al.
[24] were the two models submitted to the
National Institute for Health and Care
Excellence for apixaban reimbursement by the
National Health Service. Ten of the reviewed
articles were adaptations of these models to
different countries [10, 12–15, 18–21, 27].
Five studies compared apixaban with the
standard therapy of warfarin or acenocoumarol
[10, 14, 28, 33, 34]. Two studies compared
apixaban with aspirin [18, 35]. Three studies
compared apixaban with warfarin and aspirin
[20, 23, 27]. One study compared apixaban with
warfarin, aspirin, rivaroxaban, and dabigatran
[21]. One study compared apixaban with
rivaroxaban and dabigatran [24]. One study
compared apixaban, rivaroxaban, and
dabigatran with coumarin derivatives [17].
One study compared apixaban with vitamin K
antagonists (VKAs) [19]. Eight studies compared
warfarin with apixaban, dabigatran, and
rivaroxaban [12, 16, 22, 25, 29–32]. One study
compared apixaban with dabigatran [15], and
one study compared apixaban with rivaroxaban
[13]. Finally, two models compared the
efficiency of warfarin with genotype-guided
warfarin, apixaban, dabigatran, and
rivaroxaban, and one of them also included
edoxaban [11, 26]. All articles included both
deterministic and probabilistic sensitivity
analyses to study the model parameters that
most influenced the ICER outcome and to assess
the robustness of the model.
With the exception of eight studies, the rest
only performed a CU analysis (cost/
quality-adjusted life year [QALY]) as a measure
of the efficiency of the compared drugs. These
eight studies performed a CU analysis (cost/
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QALY) as well as a cost-effectiveness analysis
(cost/life year gained) [13–17, 19, 27, 28].
All the selected articles based their results on
the appropriate decision rates (incremental CU
and cost-effectiveness ratios). When compared
to adjusted-dose VKA (warfarin and
acenocoumarol in the great majority of the
articles), apixaban was invariably associated
with a better clinical and safety profile. In
addition, apixaban was cost-effective
compared to warfarin and aspirin and the rest
of the pharmacological strategies compared in
most of the included economic evaluations
according to the cost-effectiveness thresholds
used in various countries (Table 2).
The mean incremental QALY of apixaban
versus warfarin was of 0.219, with a range of
0.137–0.5, being dominant option in a study
[33]. When comparing apixaban with aspirin,
the mean incremental QALY was of 0.28 with a
range of 0.27–0.29, being a dominant option in
a study [35].
In general, all the studies indicated that
apixaban was cost effective with ICERs below
the willingness-to-pay (WTP) threshold, if not
dominant (Table 2). In evaluations performed
in Europe, the mean ICER was of €16,502/
QALY, with a range from €7212/QALY to
€57,245/QALY, while ICERs versus aspirin
ranged from being dominant to €7334/QALY.
In models performed in the US, ICERs of
apixaban versus warfarin ranged from being
dominant to $93,063/QALY; in addition,
apixaban was a dominant option versus
aspirin in a study performed in the US [35].
In the deterministic sensitivity analysis, the
results of these models were typically sensitive
to changes in the cost of apixaban, baseline risk
of stroke, decrease of utilities values, and time
horizon. Upon the probabilistic sensitivity
analysis, apixaban was deemed a cost-effective
strategy in 73.4% of iterations (with a range of
42–99%) compared to warfarin and 97.9% (with
a range of 96.7–99%) when compared to aspirin.
DISCUSSION
AF, the most common cardiac arrhythmia, is a
well-established risk factor for stroke. Patients
with AF are four-to-five times more likely to
have embolic stroke or transient stroke than
individuals without AF [36].
Until recently, VKAs, such as warfarin,
acenocoumarol, and phenprocoumon, were
the only available drugs for oral
anticoagulation [37]. The numerous
limitations of VKAs, such as prolonged action;
substantial variations of the anticoagulant
effect caused by numerous interactions with
food, alcohol, other drugs, or genetic variations;
and a narrow therapeutic window requiring
close laboratory monitoring with dose
adjustments, along with a perception of
increased risk of bleeding with VKA therapy,
have resulted in the underuse of oral VKAs and
suboptimal stroke prevention in patients with
AF [38, 39].
Apixaban, an oral direct factor Xa inhibitor,
is the third NOAC to receive marketing
authorization from the European Union for
the prevention of stroke and systemic
embolism in NVAF. It is the only NOAC that
has been shown to be superior to dose-adjusted
warfarin in terms of reducing stroke, systemic
embolism, major bleeding, and all-cause
mortality rates [40]. Since apixaban results in
better health outcomes than VKAs (especially
less major bleeding and a significant reduction
in the stroke rate), it is crucial for health
professionals and drug policy decision makers
to know whether or not the routine use of
apixaban in patients with NVAF is a
cost-effective therapeutic option.
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Table 2 ICER value found in each study included in the systematic literature review along with the willingness-to-pay in
the countries involved
References Country ICER results Threshold
[10] Argentina Apixa vs. War
USD 786.08/QALY
USD 11,558/QALY




Edoxa: €18,994/QALY vs. standard War
€25,000/QALY
[12] Belgium Dabi 110 mg: €13,564/QALY













[15] Spain Apixa vs. Dabi 110 mg
€1299/QALY (NHS)
Dominant (societal)




[16] UK Dabi was dominant vs. Riva, Apixa, and War £25,000/QALY
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Table 2 continued











Dabi: €11,172/QALY vs. coumarin derivatives
€20,000/QALY and €36,000/QALY
[18] Belgium Apixa vs. aspirin
€7334/QALY
€30,000/QALY
[19] The Netherlands Apixa vs. VKAs
€10,576/QALY
€20,000/QALY
[20] Sweden Apixa vs.
War: SEK 41,453/QALY
Aspirin: SEK 41,453/QALY
For War and aspirin, above SEK
35,000 and SEK 45,000 per QALY,
respectively
[21] France Aspirin, Dabi, and Riva were dominated by War
Apixa vs. War: €12,227/QALY
€30,000/QALY
[22] Norway Sequential Dabi: €15,920/QALY
Apixa: €18,955/QALY
Riva: €29,990/QALY




[23] UK Apixa vs. War: £11,909/QALY
Aspirin: £7196/QALY
£20,000/QALY




[25] Germany Dabi 110 mg: €294,349/QALY
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Table 2 continued
References Country ICER results Threshold
[26] UK Riva was dominated by Dabi and Apixa
Dabi was extensively dominated by Apixa
Genotype-guided War vs. War: £13,226/QALY
Apixa vs. genotype-guided War: £19,858/QALY
£20,000 to £30,000/QALY




[28] Australia Apixaban vs. warfarin
AUD 13,679/QALY
AUD 45,000/QALY





[30] Italy CHADS2 B 1, Apixa and Dabi, €9631 and
€7320/QALY
CHADS2 = 2, Apixa, Dabi, and Riva, €9660,
€7609, and €20,089/QALY




[31] Canada Dabi 150 mg vs. War: CAD 20,797/QALY
Dabi 110 mg, Apixa, and Riva were dominated by
Dabi 150 mg
CAD 50,000/QALY
[32] US Riva: USD 3190/QALY
Dabi: USD 11,150/QALY
Apixa: USD 15,026/QALY vs. warfarin
USD 50,000/QALY
[33] US Apixa vs. War was dominant USD 50,000/QALY
[34] US Apixa vs. War
USD 11,400/QALY
USD 50,000/QALY
[35] US Apixa vs. aspirin was dominant at 10 years USD 50,000/QALY
Apixa apixaban, AUD Australian Dollar, CAD Canadian Dollars, Dabi dabigatran, Edoxa edoxaban, ICER Incremental
cost-effectiveness ratio, LYG life years gained, NHS National Health Service, NOK Norway Krone, QALY quality-adjusted
life year, Riva rivaroxaban, SEK Swedish Krona, USD US Dollar, VKA vitamin K antagonist, War warfarin
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To answer this question, most of the
cost-effectiveness studies included in this
systematic review concur that patients treated
with this drug have a higher life expectancy and
more QALYs and life years gained than patients
treated with VKAs. In addition, they also
suggest that apixaban could result in savings
from medical costs and hospitalizations for
bleeding and routine international normalized
ratio (INR) monitoring, but results in higher
total medical costs over the patients’ lifetime,
mainly due to the increase in drug acquisition
cost and because patients live longer.
All cost-effectiveness analysis were
performed following the highest quality
standard methodology to build analytical
decision models and with scientific rigor, so
the results will be valid and accurate; in fact, the
quality of the economic evaluations was
assessed as high, yet some quality items were
not met. Moreover, most of economic
evaluations applied a probabilistic sensitivity
analysis, following the recommendations of
some country guidelines to elaborate this kind
of analysis and some health technology
assessment agencies along with a
cost-effectiveness acceptability curve, so it was
possible to estimate probabilities of cost
effectiveness at different WTP thresholds.
However, it was not possible to fully
compare the economic evaluations, as the
results were calculated on the basis of varying
alternative treatment approaches, and thereby
they were not fully homogeneous. It might be
more accurate to compare apixaban treatment
to the actual prescribing pattern of warfarin in
clinical practice, as the treatment quality in a
trial setting might be higher than in clinical
practice due to a higher degree of monitoring.
Furthermore, variations in included costs,
adverse events, annual discount rates, time
horizons, comparators, and WTP thresholds
contributed to a decrease in homogeneity,
which makes it quite impossible to directly
compare the ICERs of cost-effectiveness analysis
included. In addition, the literature
summarized in this review shows that NOACs
versus warfarin are sensitive to how well INR is
maintained with warfarin and the time frame
over which the cost-effectiveness analysis is
modeled; a longer time horizon and lower
warfarin time in therapeutic range favor the
new anticoagulants versus warfarin.
Even with these difficulties, the results of the
cost-effectiveness analyses included in this
systematic review show that apixaban could be
considered as a cost-effective therapeutic
alternative, because the cost/QALY is under
the threshold value applied in the various
countries where those analyses were
conducted (the cost that healthcare systems or
societies are willing to pay for an additional
QALY gained), indicating that apixaban
represents a good value-for-money for
preventing stroke in patients with NVAF in
several countries.
This systematic review has some limitations.
The degree of uncertainty is an important
limitation to the cost-effectiveness analysis of
apixaban included. The model parameters
obtained from the literature are imperfect or
have uncertainty; this uncertainty can be
substantial when the available research into
that particular parameter is sparse (for instance,
some model parameters, such as utilities and
event rates, employed were derived from the
1990–2000s and may not reflect contemporary
practice or outcomes).The selected studies, from
countries around the globe, differ in their
economic models, study perspectives,
comparators, drug prices, presentation of
results, and, especially, in the WTP thresholds.
This variability in methodology was thus a
challenge for comparing the different studies.
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In addition, it is difficult to analyze the
results of the studies comparing apixaban [1, 2],
dabigatran [41], and rivaroxaban [42], since
they are based on studies and trials that use
different populations with no similar basal risk,
so the cost-effectiveness of different NOACs
versus warfarin could vary in a model
depending on baseline, patient-specific risk for
ischemic stroke, and bleeding. The perspective
of the payer was used in most of the studies,
excluding costs other than direct medical costs
from the analyses; if social perspective had been
incorporated into the cost-effectiveness
analysis, the results would have probably been
different. Finally, all published models utilize a
base case of a 70-year-old individual with AF.
Given the need for anticoagulation for patients
of different ages (in many occasion in patients
below those age), it would be necessary to build
models where base-case characteristics are
obtained from unselected real-world
population with AF that needs anticoagulation.
CONCLUSIONS
Different cost-effectiveness analyses suggest
that apixaban is a cost-effective therapeutic
option versus the gold standard therapy for
stroke prevention in patients with NVAF in
several countries. While variations in clinical
events and costs do influence the efficiency rate
of one drug relative to another, apixaban
consistently appears to be most cost effective
than VKAs and other NOACs.
The generalizability of the results of these
cost-effectiveness analyses may be limited to
the whole population of patients with NVAF,
because efficacy and safety data are mainly
restricted to patients who met inclusion
criteria for the landmark apixaban trials.
Furthermore, there are important differences
between clinical trials and real-world practice
that could produce different results if the
cost-effectiveness analyses were performed
using effectiveness data coming from daily
medical practice instead of clinical trials. For
these reasons, it is anticipated that data from
daily medical practice in a real-world context
will be very important for determining the real
clinical and cost-effectiveness value of
apixaban, thus helping to properly position
apixaban within the current existing
therapeutic arsenal for preventing stroke in
patients with NVAF in several countries.
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